Annual patient perspectives research initiative continues to capture real-world experiences as treatment and diagnostic options for steatotic liver disease evolve in the United States

March 16, 2026; Boise, IDAHO — The Fatty Liver Foundation (FLF) today announced the launch of the 2026 edition of its nationwide patient research initiative, The State of Steatotic (Fatty) Liver Care in America: Patient Perspectives Research. Now entering its fifth year, the survey continues FLF commitment to understanding the lived experiences of people living with steatotic liver disease across the United States, including metabolic dysfunction associated steatotic liver disease (MASLD), metabolic dysfunction associated steatohepatitis (MASH), alcohol-associated liver disease (ALD), and the emerging metabolic dysfunction and alcohol-associated liver disease (MetALD) subtype.

Nationwide study reveals persistent diagnostic delays, specialist access barriers, and unmet psychosocial needs among Americans living with steatotic liver disease

NOVEMBER 5, 2025, Boise, IDAHO –  The Fatty Liver Foundation (FLF) will present findings from its State of Steatotic (Fatty) Liver Care in America: 2022–2025 Patient Perspectives Research at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2025 in Washington, DC. The abstract, titled “Shifting Trends in U.S. Steatotic Liver Disease Care: Patient-Reported Insights from the 2022–2025 SLD Care Survey” (Publication No. 2592), will be presented as part of the MASLD/MASH – Epidemiology and Natural History, Prevention and Outcomes poster session Saturday, November 8, 2025, from 8:00 AM to 5:00 PM at the Walter E. Washington Convention Center.

NOVEMBER 3, 2025, Boise, IDAHO – The Fatty Liver Foundation (FLF) will have a major presence at this year’s American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® (TLM) in Washington, D.C., November 7–11, 2025. FLF will introduce the inaugural cohort of Fellows of the Dr. Stephen A. Harrison Patient Advocacy Fellowship, present two scientific posters, host three Community Conversations, and participate in several sessions as part of AASLD’s Patient Programming.

April 16, 2025; Boise, IDAHO — The Fatty Liver Foundation (FLF) today announces the launch of the fourth annual "The State of Steatotic (Fatty) Liver Care in America: Patient Perspectives Research", a nationwide survey designed to capture the lived experiences of individuals affected by metabolic dysfunction-associated steatohepatitis (MASH), metabolic dysfunction-associated steatotic liver disease (MASLD), and alcohol-associated forms of steatotic liver disease.

November 7, 2024; Boise, IDAHO — The Fatty Liver Foundation (FLF) will present new insights into the evolving experiences of individuals with Steatotic Liver Disease (SLD), including Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), Metabolic Dysfunction-Associated Steatohepatitis (MASH), and Alcohol-Associated Liver Disease (ALD), at this year’s The American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® (TLM), held from November 15-19 in San Diego, California. The poster presentation, titled "Evolution of MASLD/MASH Patient Experiences: Insights from ‘The State of Steatotic (Fatty) Liver Care in America’ Surveys 2022-2024" (Abstract Number: 2299), provides a comprehensive look at patient-reported challenges, access to care, and progress in SLD management across the U.S.

FLF unveils the third-year launch of “The Steatotic (Fatty) Liver Care in America: Patient Perspectives Research,” a pioneering nationwide initiative that empowers MAFLD/MASH patients to share their experiences and drive ongoing improvements in patient care

April 19, 2024; Boise, IDAHO — In observance of World Liver Day, the Fatty Liver Foundation (FLF) proudly announces the launch of this year’s "The State of Steatotic (Fatty) Liver Care in America: Patient Perspectives Research." This pivotal, nationwide survey comes at a transformative time with the introduction of Rezdiffra™, the first FDA-approved treatment in the U.S. for adults with metabolic dysfunction-associated steatohepatitis (MASH) who have moderate to advanced liver fibrosis, used in conjunction with diet and exercise.

FLF unveils the second-year launch of The State of NAFLD/NASH Care in America™, a pioneering nationwide initiative that empowers NAFLD/NASH patients to share their experiences and drive ongoing improvements in patient care

April 10, 2023; Boise, IDAHO — The Fatty Liver Foundation (FLF) today announces the second-year launch of The State of NAFLD/NASH Care in AmericaTM, a pioneering national initiative that aims to make a significant impact within the NAFLD/NASH patient community. This initiative surveys the real-life experiences of adults with NAFLD/NASH across the United States, promoting the ongoing development and implementation of practical solutions to improve diagnosis, treatment, care, and support for those affected by these conditions.

The Fatty Liver Foundation (FLF) today announced the launch of The State of NAFLD/NASH Care in America™, a first-of-its-kind national initiative that aims to make a big impact within the NAFLD/NASH community by surveying the lived experiences of adults with NAFLD/NASH in the United States and fostering the continuous development and integration of actionable solutions to improve the diagnosis, treatment, care, and support for people with NAFLD/NASH.